{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.16","value":"93.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods. AUC (0-336h) was derived only for the Belantamab mafodotin 2.5mg/kg + Len/Dex SPLIT cohort.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0, 2, and 24 Hours Post Dose on Cycle 1 Day 1; Cycle 1 Day 4; Cycle 1 Day 8; Cycle 1 Day 11; Cycle 1 Day 14","title":"AUC (0-336h) for Belantamab Mafodotin (Cys-mcMMAF), Treatment A","type":"SECONDARY","unitOfMeasure":"h*ug/mL"}